BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
这些演讲重点分析了BRUKINSA与其他用于治疗慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）的布鲁顿酪氨酸激酶抑制剂（BTKI）相比的疗效和安全性。
"At this year's ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA's uniquely differentiated clinical profile," Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. "These new analyses, which highlight improved PFS and response rates and a low usage of antihypertensive medicines, provide valuable insights for oncologists to consider when making treatment decisions for their patients with CLL and SLL."
百济神州血液学首席医学官梅尔达德·莫巴舍尔医学博士、M.P.H. M.P.H.：“在今年的ASCO上，多场演讲继续为我们提供了大量证据，证明了BRUKINSA独特的差异化临床特征。”“这些新分析突显了PFS和反应率的提高以及降压药物的使用率较低，为肿瘤学家在为CLL和SLL患者做出治疗决策时提供了宝贵的见解。”